Assessing Lysosomal Disorders in the NGS Era: Identification of Novel Rare Variants - PubMed

Assessing Lysosomal Disorders in the NGS Era: Identification of Novel Rare Variants - PubMed

Assessing Lysosomal Disorders in the NGS Era: Identification of Novel Rare Variants

Marisa Encarnação 1 2 3, Maria Francisca Coutinho 1 3, Lisbeth Silva 1 2, Diogo Ribeiro 1, Souad Ouesleti 4, Teresa Campos 5, Helena Santos 6, Esmeralda Martins 7, Maria Teresa Cardoso 5, Laura Vilarinho 1 2 3, Sandra Alves 1 3

Affiliations 

• PMID: 32883051
 
• DOI: 10.3390/ijms21176355

Free article

Abstract

Lysosomal storage diseases (LSDs) are a heterogeneous group of genetic disorders with variable degrees of severity and a broad phenotypic spectrum, which may overlap with a number of other conditions. While individually rare, as a group LSDs affect a significant number of patients, placing an important burden on affected individuals and their families but also on national health care systems worldwide. Here, we present our results on the use of an in-house customized next-generation sequencing (NGS) panel of genes related to lysosome function as a first-line molecular test for the diagnosis of LSDs. Ultimately, our goal is to provide a fast and effective tool to screen for virtually all LSDs in a single run, thus contributing to decrease the diagnostic odyssey, accelerating the time to diagnosis. Our study enrolled a group of 23 patients with variable degrees of clinical and/or biochemical suspicion of LSD. Briefly, NGS analysis data workflow, followed by segregation analysis allowed the characterization of approximately 41% of the analyzed patients and the identification of 10 different pathogenic variants, underlying nine LSDs. Importantly, four of those variants were novel, and, when applicable, their effect over protein structure was evaluated through in silico analysis. One of the novel pathogenic variants was identified in the GM2A gene, which is associated with an ultra-rare (or misdiagnosed) LSD, the AB variant of GM2 Gangliosidosis. Overall, this case series highlights not only the major advantages of NGS-based diagnostic approaches but also, to some extent, its limitations ultimately promoting a reflection on the role of targeted panels as a primary tool for the prompt characterization of LSD patients.

Keywords: CLN7; GM2 Gangliosidosis; GM2A gene; bioinformatics analysis; diagnostics odyssey; lysosomal storage diseases (LSDs); molecular genetic testing (MGT); next-generation sequencing (NGS).

Similar articles

• Sensitivity, advantages, limitations, and clinical utility of targeted next-generation sequencing panels for the diagnosis of selected lysosomal storage disorders.

  Málaga DR, Brusius-Facchin AC, Siebert M, Pasqualim G, Saraiva-Pereira ML, Souza CFM, Schwartz IVD, Matte U, Giugliani R.Genet Mol Biol. 2019;42(1 suppl 1):197-206. doi: 10.1590/1678-4685-GMB-2018-0092. Epub 2019 Apr 11.PMID: 30985853 Free PMC article.
• Assessment of a targeted resequencing assay as a support tool in the diagnosis of lysosomal storage disorders.

  Fernández-Marmiesse A, Morey M, Pineda M, Eiris J, Couce ML, Castro-Gago M, Fraga JM, Lacerda L, Gouveia S, Pérez-Poyato MS, Armstrong J, Castiñeiras D, Cocho JA.Orphanet J Rare Dis. 2014 Apr 25;9:59. doi: 10.1186/1750-1172-9-59.PMID: 24767253 Free PMC article.
• Lysoplex: An efficient toolkit to detect DNA sequence variations in the autophagy-lysosomal pathway.

  Di Fruscio G, Schulz A, De Cegli R, Savarese M, Mutarelli M, Parenti G, Banfi S, Braulke T, Nigro V, Ballabio A.Autophagy. 2015;11(6):928-38. doi: 10.1080/15548627.2015.1043077.PMID: 26075876 Free PMC article.
• [Lysosomal storage diseases: A brief summary].

  Bornemann A, Harzer K.Pathologe. 2015 Sep;36(5):485-93. doi: 10.1007/s00292-015-0053-8.PMID: 26314267 Review. German.
• Lysosomal storage disorders: molecular basis and laboratory testing.

  Filocamo M, Morrone A.Hum Genomics. 2011 Mar;5(3):156-69. doi: 10.1186/1479-7364-5-3-156.PMID: 21504867 Free PMC article. Review.